Affordable Access

deepdyve-link
Publisher Website

The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance.

Authors
  • Recabal, Pedro1
  • Assel, Melissa2
  • Sjoberg, Daniel D2
  • Lee, Daniel3
  • Laudone, Vincent P4
  • Touijer, Karim4
  • Eastham, James A4
  • Vargas, Hebert A5
  • Coleman, Jonathan4
  • Ehdaie, Behfar6
  • 1 Urology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, New York; Urology Service, Fundacion Arturo Lopez Perez, Santiago, Chile. , (Chile)
  • 2 Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • 3 Department of Urology, Weill-Cornell Medical College, New York Presbyterian Hospital, New York, New York.
  • 4 Urology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, New York.
  • 5 Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • 6 Urology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: [email protected]
Type
Published Article
Journal
The Journal of urology
Publication Date
Aug 01, 2016
Volume
196
Issue
2
Pages
374–381
Identifiers
DOI: 10.1016/j.juro.2016.02.084
PMID: 26920465
Source
Medline
Keywords
License
Unknown

Abstract

Magnetic resonance imaging targeted biopsies increased the detection of higher grade cancer among men on active surveillance compared to systematic biopsy alone. However, a clinically relevant proportion of higher grade cancer was detected using only systematic biopsy. Despite the improved detection of disease progression using magnetic resonance imaging targeted biopsy, systematic biopsy cannot be excluded as part of surveillance for men with low risk prostate cancer.

Report this publication

Statistics

Seen <100 times